The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

First new drug in 30 years to slow kidney disease in type 1 diabetes ...

Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial ...

Early albuminuria reduction with finerenone (Kerendia) drove protection against chronic kidney disease (CKD) progression in people with type 2 diabetes, according to a post-hoc mediation analysis. At ...

Finerenone has been shown to reduce urinary albumin excretion in adults with type 1 diabetes and chronic kidney disease (CKD) ...

New signals of a potential additive benefit from the nonsteroidal mineralocorticoid antagonist finerenone (Kerendia) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with type 2 ...

Compared with monotherapy, finerenone plus empagliflozin was associated with improved kidney outcomes in T2D and CKD regardless of GLP-1RA use. Compared with monotherapy and regardless of prior ...

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA ® (finerenone) significantly reduced urine ...

hands holding red heart and kidney with stethoscope, world kidney day In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials. Finerenone ...

Please provide your email address to receive an email when new articles are posted on . The nonsteroidal mineralocorticoid receptor antagonist finerenone reduced CV event risk by 13% for adults with ...

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.